1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Zynex, Inc.

Zynex, Inc.

ZYXIQ
Zynex, Inc.US flagOther OTC
0.06
USD
+0.00
- -
1.69MMarket Cap
Zynex, Inc.
ZYXIQ
(Other OTC)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
0.56
0.72
1.01
1.16
0.63
0.32
0.34
0.39
0.66
0.89
1.27
2.15
3.4
4.11
5.18
6.02
3.49
Revenue per Share
0.07
0.01
0.05
0.05
-0.21
-0.18
-0.08
- -
0.21
0.27
0.27
0.24
0.45
0.44
0.27
0.09
-2.38
Basic EPS, GAAP
0.08
-0.04
-0.05
-0.05
-0.03
0.02
0.01
0.04
0.23
0.23
0.17
- -
0.17
0.35
0.47
0.38
-0.68
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.06
- -
- -
0.09
- -
- -
- -
Dividend per Share
0.09
0.1
0.15
0.19
-0.02
-0.2
-0.29
-0.28
-0.07
0.14
0.4
0.63
- -
0.44
0.75
0.93
-1.4
Book Value per Share
0.23
0.24
0.3
0.34
0.14
-0.04
-0.12
-0.11
0.14
0.26
0.55
1.53
1.14
0.96
0.49
0.25
-1.33
Tangible Book Value per Share
33
34
34
34
34
34
34
34
35
36
36
37
38
38
36
32
31
Basic Weighted Avg Shares
19
24
34
40
22
11
12
13
23
32
45
80
130
158
184
192
108
Sales/Revenue/Turnover
20.42
6.48
9.08
6.9
-35.05
-51.25
-21.31
4.81
38.17
32.49
24.34
12.79
17.16
14.5
5.85
3.11
-34.35
Operating Margin (%)
1
1
1
1
1
1
- -
- -
- -
- -
1
2
2
3
4
5
5
Depreciation Expense
2
- -
2
2
-7
-6
-3
- -
7
10
9
9
17
17
10
3
-74
Net Income, GAAP
37.69
73.78
40.85
33.73
- -
- -
- -
17.86
1.72
6.5
20.51
10.63
23.21
23.2
22.63
17.45
- -
Effective Tax Rate (%)
12.75
1.45
4.58
3.92
-33.67
-55.76
-25.01
0.52
31.43
29.93
20.87
11.33
13.13
10.78
5.28
1.56
-68.35
Profit Margin (%)
6
7
8
9
4
-2
-5
-4
4
7
17
53
60
48
69
58
-42
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
3
5
27
19
72
70
8
LT Debt
7
8
10
12
5
-1
-4
-4
5
9
20
57
74
66
46
36
-41
Total Equity
29.67
4.2
14.86
11.51
- -
- -
- -
- -
384.43
102.62
46.26
20.62
19.54
17.05
7.64
4.25
- -
Return on Invested Capital (%)
77.5
9.66
26.43
17.18
- -
- -
- -
-5.78
-197.04
305
69.17
36.52
52.11
43.92
14.39
4.8
- -
Return on Capital (%)
112.72
10.59
36.7
26.68
- -
- -
- -
- -
- -
- -
98.42
47.94
145.51
199.07
44.34
10.58
-21.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
4
64
64
LT Borrowings
59
- -
- -
LT Finance Leases
10
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
70
81
45

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
56
46
37
Cash, Cash Equivalents & STI
24
18
13
Accounts Receivable, Net
14
10
7
Inventories
14
12
12
Total Current Liabilities
16
74
79
Payables & Accruals
12
10
15
ST Debt
4
64
64
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.28%
31.2%
-22.59%
Free Cash Flow
-318.41%
-778.27%
-26.63%
Net Income, GAAP
1,041.92%
-5.68%
-69.24%
Sales/Revenue/Turnover
35.49%
36.22%
4.36%
Total Cash Common Dividend
- -
- -
200%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
42
45
50
47
184
2024
47
50
50
46
192
2025
27
22
13
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.04
0.09
0.1
- -
0.27
2024
- -
0.04
0.07
-0.02
0.09
2025
-0.33
-0.66
-1.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
ClouDr Group Limited (9955.HK)
Medios AG (0QB4.L)
Arjo AB (publ) (ARRJF)
Apex Healthcare Berhad (7090.KL)
Oriola Oyj (0NES.L)
Cowealth Medical Holding Co., Ltd. (4745.TWO)
Business
Zynex, Inc. engages in the design, manufacture, marketing, and sale of medical devices focused on non-invasive pain management, physical rehabilitation, and patient monitoring. The company operates primarily through electrotherapy and related medical devices that use technologies such as neuromuscular electrical stimulation, electrical nerve stimulation, interferential current, and electromyography to alleviate pain, support rehabilitation after stroke or spinal cord injury, and assist in monitoring patients’ physiological status. Core product families include NexWave, NeuroMove, InWave, E-Wave, M-Wave, and NiCO pulse oximeters, complemented by private-labeled electrode supplies, batteries, and distributed products such as braces and related rehabilitation accessories. Zynex markets these devices to clinics, hospitals, and end users across the United States, with additional distribution through partner channels and international opportunities where applicable, and maintains a portfolio of monitoring solutions including CM-series analyzers and oximetry equipment. The company is headquartered in Aurora, Colorado, and serves customers in North America, with ongoing initiatives to expand adoption of its electrotherapy platforms and monitoring technologies as alternatives or adjuncts to traditional pharmacologic therapies. Zynex was founded in 1996 and operates as a single primary business segment comprising medical devices for pain management and rehabilitation, supported by a spectrum of related supplies and monitoring products. The company pursues strategic alignments and product development initiatives to enhance clinical outcomes, expand into new care settings, and advance non-invasive treatment modalities within its target markets. Recent organizational and strategic activities focus on optimizing production and distribution, advancing human clinical data for key products, and pursuing partnerships to broaden market access and product integration within healthcare networks. These efforts are intended to strengthen Zynex’s position in the electrotherapy and rehabilitation markets and to support continued growth in its core device and supply offerings.

Company News

APIChatGPT

  • newsfilecorp.com

    ZYXIQ CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

  • feeds.newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit – ZYXIQ

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • feeds.newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • newsfilecorp.com

    ZYXIQ SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    ZYXIQ Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zynex, Inc. Securities Lawsuit — The Gross Law Firm

  • prnewswire.com

    ZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    ZYXIQ INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zynex, Inc.

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • newsfilecorp.com

    ZYXIQ EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • newsfilecorp.com

    ZYXIQ DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

  • prnewswire.com

    ZYXIQ Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Zynex, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

  • globenewswire.com

    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zynex, Inc. (ZYXIQ)